IGI Logo

Morepen Laboratories is pleased to announce the launch of four new products—Ticapen, UdoFix, LycoMore, Acifix in the month of April 2025 to cater the domestic market in addition to Empamore launched last month continuing its commitment to offer innovative latest products marking an another milestone reinforcing the doctor and patient trust. These new launches reflect our unwavering focus on research-led innovation, clinical excellence, and affordable healthcare access, addressing critical needs in cardiology, hepatology, nutrition, and diabetology. 

 

This strategic expansion reinforces Morepen’s commitment to scaling its finished dosages business while continuing to invest in cutting-edge R&D that powers a robust pipeline of differentiated, high quality medicines. Importantly, all APIs used in these products are manufactured in-house by Morepen at its world-class, USFDA-approved plants, ensuring consistent quality and supply chain control. 

 

As India’s #1 exporter of APIs for six globally used molecules—Loratadine, Montelukast, Desloratadine, Atorvastatin, Rosuvastatin, and Fexofenadine—Morepen has a presence in 82 countries, backed by an annual API manufacturing capacity of 144 metric tons. Its integrated capabilities across the pharmaceutical value chain give it a unique competitive edge in both regulated and emerging markets like the US, Europe, Japan, China, and Russia. With a current formulation business size of approximately Rs.325 crore, the company is now accelerating toward a Rs.1,000 crore target over the next five years—driven by deeper market penetration, an expanded field force, and a growing portfolio of cost-efficient, globally compliant therapies.

 

 

 

Above views are of the author and not of the website kindly read disclaimer